REG - Belluscura PLC - Statement re proposed imposition of Tariffs

BelluscuraAnnouncement

08/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250408:nRSH0116Ea&default-theme=true

RNS Number : 0116E  Belluscura PLC  08 April 2025

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO
CONSTITUTE INSIDE INFORMATION PURSUANT TO ARTICLE 7 OF EU REGULATION 596/2014
AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION
(WITHDRAWAL) ACT 2018 AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT
VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW
CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

8 April 2025

 

 

Belluscura plc

("Belluscura" or the "Company")

 

Statement re proposed imposition of Tariffs

 

Belluscura plc (AIM: BELL), a UK medical device company focused on developing
oxygen enrichment technology spanning broad industries and therapies, notes
the proposed imposition of tariffs on imports to the United States of America
announced by the US Administration last week.

 

The Company is currently assessing the potential financial implications, risks
and opportunities of the imposition of tariffs, in particular the 54% tariff
(previously 20%) for goods imported from China, in which a significant
proportion of the Company's Portable Oxygen Concentrators, raw materials and
component parts are currently manufactured.

In the light of the above, the Company withdraws its previous market guidance
for the current year ending 31 December 2025 (as referred to in its
notification of 6 February 2025).

The Company expects to make a further announcement once it has been able to
better assess the situation, including possible subsequent developments.

 

For further information please contact:

 

 Belluscura plc                                              Tel: +44 (0)20 3128 8100
 Paul Tuson, Chairman

 Robert Rauker, Chief Executive Officer

 Simon Neicheril, Chief Financial Officer

                                                             Tel: +44 (0)20 3368 3550

 SPARK Advisory Partners Limited

 Nominated Adviser
 Neil Baldwin / Jade Bayat

                                                             Tel: +44 (0)20 3903 7715

 Dowgate Capital Limited

 Joint Broker
 James Serjeant / Colin Clime (Sales and Corporate Broking)

 Russell Cook / Daniel Ingram (Corporate Finance)

 Allenby Capital Ltd                                         Tel: +44 (0)20 3328 5656

 Joint Broker
 Guy McDougall / Amrit Nahal (Sales and Corporate Broking)

 Jeremy Porter / Lauren Wright (Corporate Finance)

 MHP                                                         Tel: +44 (0)20 3128 8100

 Financial PR & Investor Relations                           email: Belluscura@mhpgroup.com (about:blank)
 Katie Hunt/Matthew Taylor

 

For further information, please visit https://ir.belluscura.com/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRUPURUCUPAPGM